Prolongation of Off-Cycle Interval by Finasteride Is Not Associated with Survival Improvement in Intermittent Androgen Deprivation Therapy in LNCaP Tumor Model

September 2009 in “ The Prostate ”

Yujuan Wang, Shubham Gupta, Vi N. Hua, Raquel Ramos-Garcia, Daniel H. Shevrin, Borko Jovanovic, Joel B. Nelson, Zhou Wang

finasteride 5α-reductase inhibition androgen deprivation therapy LNCaP tumor model Propecia IADT

TLDR Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.

This study investigated whether prolonging the off-cycle interval by finasteride is associated with survival improvement in intermittent androgen deprivation therapy (IADT) in LNCaP tumor model. The results showed that prolonging the off-cycle interval by finasteride did not improve survival in IADT in LNCaP tumor model. The study concluded that maximum possible lengthening of the off-cycle by 5α-reductase inhibition is not associated with survival improvement in this animal model.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period

32 citations, May 2006 in “The Journal of Urology”

Using finasteride with TIP extends time off period for prostate cancer patients.

research Side Effects of Androgen Deprivation Therapy: Monitoring and Minimizing Toxicity

228 citations, February 2003 in “Urology”

Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.

Related Community Posts Join

6 / 1000+ results

community Trying to understand finasteride side effects and post finasteride syndrome

in Finasteride/Dutasteride 73 upvotes 4 years ago

The conversation discusses the side effects of finasteride, including low libido and erectile dysfunction, and the possibility of these effects being permanent, known as post-finasteride syndrome (PFS). Some users report personal experiences with PFS and debate whether the condition is real, with varying opinions on the reversibility of side effects and the role of individual biology.

community New and Interesting HairLoss Studies/Papers/Reviews

in Treatment 42 upvotes 4 years ago

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

community A meta analysis of 18 popular hair loss treatments. An 2022 guide on efficacy. From finasteride and minoxidil to caffeine shampoo, saw palmetto and biotin. 96 Scientific References included.

in Research/Science 101 upvotes 2 years ago

Most hair loss treatments are ineffective; only finasteride, dutasteride, and minoxidil show effectiveness.

community Having androgen receptor density and sensitivity at wrong f*ing place

in Satire 7 upvotes 2 months ago

The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.

community Dutasteride SAVES your hair follicles: MAJOR BS on people who say it destroyed their hair permanently.

in Finasteride/Dutasteride 160 upvotes 1 year ago

The conversation discusses the effectiveness of hair loss treatments, specifically finasteride and dutasteride. The conclusion is that dutasteride significantly reduces DHT levels and may be more effective than finasteride for long-term hair retention, with some users reporting personal experiences and side effects.

community Everyone is ignoring that plasma finasteride levels are 100x lower with topical compared to oral.

in Research/Science 138 upvotes 5 months ago

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

Related Research

3 / 3 results

research Key Targets of Hormonal Treatment of Prostate Cancer: The Androgen Receptor and 5α-Reductase

29 citations, July 2009 in “BJU international”

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

research Steroidogenesis Inhibitors Alter But Do Not Eliminate Androgen Synthesis Mechanisms During Progression to Castration-Resistance in LNCaP Prostate Xenografts

57 citations, April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology”

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

research Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period

32 citations, May 2006 in “The Journal of Urology”

Using finasteride with TIP extends time off period for prostate cancer patients.